Effect of in vivo therapy with a CD8 monoclonal antibody on delayed engraftment after autologous bone marrow transplantation.
Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+, CD57+ cells from the blood and bone marrow in five cases, a partial clearance in one, the absence of clearance in one and a modulation in the last case. No toxic side effects were observed. Platelet recovery was observed in only two patients, but long-lasting granulocyte recovery was seen in six of the cases from day 6 to day 30 after the beginning of CD8 infusion (median = 17 days).
Favrot
M
M
Unité Fonctionnelle de Transplantation médullaire, Centre Léon Berard, Lyon, France.
Philip
T
T
Combaret
V
V
Lemerle
J
J
Marie
J P
JP
Bernard
A
A
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte; D016026:Bone Marrow Transplantation; D016827:CD8 Antigens; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007167:Immunotherapy; D008214:Lymphocytes / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014182:Transplantation, Autologous
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D016827:CD8 Antigens